Insight Molecular Diagnostics (LTS:0KCC) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0KCC Insight Molecular Diagnostics Inc LTS:0KCC
51 GF Score
Price $4.63
GF Value $1.24
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Insight Molecular Diagnostics FFO per Share?

FFO per Share only applies to REITs.

LTS:0KCC
51GF Score
Insight Molecular Diagnostics Inc LTS:0KCC
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Insight Molecular Diagnostics (LTS:0KCC) Overvalued in 2026?

Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued. The current stock price of $4.63 is trading 273.4% above its estimated GF Value™ of $1.24. GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.

Key valuation signals for LTS:0KCC:

  • FFO per Share:
  • GF Value™: $1.24 vs. price of $4.63 (273.4% above fair value)
  • GF Score™: 51/100 with 7 warning signs

No single metric tells the full story. See the LTS:0KCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Insight Molecular Diagnostics Business Description

Other Exchanges IMDX:USA7OC0:Germany
Address 2 International Plaza Drive, Suite 510, Nashville, TN, USA, 37217
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
51GF Score

Get the complete analysis for LTS:0KCC

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.63
Price
$1.24
GF Value